Home
University of Bergen
Amani Thomas Mori's picture

Amani Thomas Mori

Researcher, Senior Researcher in Essential NCD project - Tanzania
Department of Global Public Health and Primary Care
Bergen Centre for Ethics and Priority Setting (BCEPS)
  • E-mailamani.mori@uib.no
  • Visitor Address
    Alrek helseklynge, blokk D, Årstadveien 17
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2023). Whether or not to enroll, and stay enrolled? A Tanzanian cross-sectional study on voluntary health insurance. Health Policy OPEN.
  • Show author(s) (2023). Projected health impact of post-discharge malaria chemoprevention among children with severe malarial anaemia in Africa. Nature Communications. 1-10.
  • Show author(s) (2023). Mandatory health insurance for the informal sector in Tanzania—has it worked anywhere! Frontiers in Health Services.
  • Show author(s) (2023). Healthcare utilization and catastrophic health expenditure in rural Tanzania: does voluntary health insurance matter? BMC Public Health.
  • Show author(s) (2023). Estimating the burden of severe malarial anaemia and access to hospital care in East Africa. Nature Communications.
  • Show author(s) (2023). Cost of image-guided percutaneous nephrostomy among cervical cancer patients at Muhimbili National Hospital in Tanzania. Cost Effectiveness and Resource Allocation. 8 pages.
  • Show author(s) (2022). Post-discharge morbidity and mortality in children admitted with severe anaemia and other health conditions in malaria-endemic settings in Africa: a systematic review and meta-analysis. The Lancet Child and Adolescent Health. 474-483.
  • Show author(s) (2022). Health Technology Assessment in Tanzania: Capacity and experience of HTA committee members. Journal of Global Health Economics and Policy.
  • Show author(s) (2022). Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis. EClinicalMedicine. 1-13.
  • Show author(s) (2022). Domestic funding opportunities for Tanzania as five new Middle-Income countries brace for reduced Gavi support for immunization. Vaccine. 3278-3285.
  • Show author(s) (2021). Implementing standard antenatal care interventions: health system cost at primary health facilities in Tanzania. Cost Effectiveness and Resource Allocation. 8 pages.
  • Show author(s) (2021). Economic consequences of caesarean section delivery: evidence from a household survey in Tanzania. BMC Health Services Research. 1-11.
  • Show author(s) (2021). Do household perceptions influence enrolment decisions into community-based health insurance schemes in Tanzania? BMC Health Services Research. 11 pages.
  • Show author(s) (2021). ABC-VEN Analysis of Medicine Expenditure at Mwananyamala Regional Hospital in Tanzania. Modern Economy.
  • Show author(s) (2020). Vaccine storage and distribution between expanded program on immunization and medical store department in Tanzania: a cost-minimization analysis. Vaccine. 8130-8145.
  • Show author(s) (2020). Prices of medicines for the management of pain, diabetes and cardiovascular diseases in private pharmacies and the national health insurance in Tanzania. International Journal for Equity in Health. 1-9.
  • Show author(s) (2019). The cost-effectiveness of incentive-based active case finding for tuberculosis (TB) control in the private sector Karachi, Pakistan. BMC Health Services Research.
  • Show author(s) (2017). Cost-benefit and extended cost-effectiveness analysis of a comprehensive adolescent pregnancy prevention program in Zambia: study protocol for a cluster randomized controlled trial. Trials. 1-10.
  • Show author(s) (2016). Equity impact analysis of medical approaches to cardiovascular diseases prevention in Tanzania. Social Science and Medicine. 208-217.
  • Show author(s) (2016). Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: A Markov modelling study. BMC Health Services Research.
  • Show author(s) (2016). Budget impact analysis of using dihydroartemisinin–piperaquine to treat uncomplicated malaria in children in Tanzania. PharmacoEconomics (Auckland). 303-314.
  • Show author(s) (2014). The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania. PLOS ONE. 10 pages.
  • Show author(s) (2014). Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malaria Journal.
  • Show author(s) (2013). Role of pharmacoeconomics in developing countries. Farmeconomia. Health economics and therapeutic pathways. 3-5.
  • Show author(s) (2013). Reforms: a quest for efficiency or an opportunity for vested interests'? a case study of pharmaceutical policy reforms in Tanzania. BMC Public Health. 6 pages.
  • Show author(s) (2012). Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework. Implementation Science. 8 pages.
Lecture
  • Show author(s) (2019). Farmasøyter med og uten genser: Hvordan farmasiutdanningene i Bergen og Dar es Salaam blir bedre av et nord-sør samarbeid .
Academic lecture
  • Show author(s) (2021). Epidemiological impact of PMC.
  • Show author(s) (2018). Post-discharge risks of morbidity and mortality in children in malaria endemic settings in Africa: A systematic review and meta-analysis - Oral presentation.
  • Show author(s) (2018). Post-discharge Malaria Chemoprevention for Children Under the Age of 5 years in Africa.
Doctoral dissertation
  • Show author(s) (2015). Pharmacoeconomics and Formulary Decision-Making in Tanzania. Generating Evidence for Antimalarial Drugs.
Academic literature review
  • Show author(s) (2020). Patient and health system costs of managing pregnancy and birth-related complications in sub-Saharan Africa: A systematic review. Health Economics Review. 1-15.
  • Show author(s) (2018). Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: A retrospective review of data from the regulatory authority. BMJ Open. 1-7.
  • Show author(s) (2012). Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Medical Informatics and Decision Making. 9 pages.

More information in national current research information system (CRIStin)